{"ticker": {"uuid": "7981af04-6f80-40e0-b579-db2b676d9704", "symbol": "XCUR", "name": "Exicure Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "XCUR stock trades on limited evidence as Exicure waits for filings", "summary": "Exicure Inc. (XCUR) stock is currently trading with limited market drivers, with the company's investor relations site being the primary source of information. The article emphasizes that without recent filings, fresh market data, or updated operational figures, any analysis must", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/xcur-stock-trades-on-limited-evidence-as-exicure-waits-for-filings/69855923", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-23T19:09:28", "published_display": "23 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XCUR|Exicure Inc|Price:1.700|Chg%:-0.010", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9VTDlZOGZJNzNBMFJpVUM5Q01aVzd6MmlxdE1Yekd2cks0dzUyNm9NS3BTNFdER3hpbVVCZGdnLU1MOVh4Sm5DSzZsVUZ3YXZ6U3FNUFY1TjZXQQ?oc=5", "source_name": "TradingKey", "published_at": "2026-07-23T07:00:00+00:00", "published_display": "23 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A EXICURE For: 17 July By Investing.com", "summary": "This article announces the filing of Form 13D/A for EXICURE, dated July 17. The brief report from Investing.com provides a headline update regarding this financial filing.", "url": "https://ng.investing.com/news/stock-market-news/form-13da-exicure-for-17-july-93CH-2605501", "source_name": "Investing.com Nigeria", "published_at": "2026-07-18T14:41:45", "published_display": "18 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Exicure Inc For: 17 July By Investing.com", "summary": "This article provides notification of a Form 4 filing for Exicure Inc. from July 17. Form 4 filings are used to report changes in beneficial ownership of a company's securities by insiders. The article also lists the current stock performance of XCUR for the day mentioned.", "url": "https://ng.investing.com/news/stock-market-news/form-4-exicure-inc-for-17-july-93CH-2605739", "source_name": "Investing.com Nigeria", "published_at": "2026-07-17T21:44:00", "published_display": "17 Jul 2026 21:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure, Inc. (XCUR) holder Exicure HiTron regains 623,275 returned shares", "summary": "Exicure HiTron Inc., a major shareholder of EXICURE, INC. (XCUR), has reported the acquisition of 623,275 common shares through a series of \"code J\" transactions between June 23 and July 8, 2026, each priced at $4.50. These shares were returned to Exicure HiTron due to share tran", "url": "https://www.stocktitan.net/sec-filings/XCUR/form-4-exicure-inc-insider-trading-activity-4d6da06defb5.html", "source_name": "Stock Titan", "published_at": "2026-07-17T20:39:30", "published_display": "17 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure HiTron boosts Exicure (XCUR) holding to 2.22M shares, 34.87%", "summary": "Exicure HiTron Inc. has increased its beneficial ownership in Exicure, Inc. (XCUR) to 34.87%, holding 2,222,224 shares after amending previous share transfer transactions. This change resulted from five purchasers returning an aggregate of 623,277 Exicure shares to Exicure HiTron", "url": "https://www.stocktitan.net/sec-filings/XCUR/schedule-13d-a-exicure-inc-amended-major-shareholder-report-94ca3cb0d3a4.html", "source_name": "Stock Titan", "published_at": "2026-07-17T16:39:30", "published_display": "17 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Trending Stocks Today | Exicure Shoots up 31.39% Post-Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOU1F2ekItTVVJS3lyWVc4RmxZSndvVy1MMlAyWWJNal9iQ0RsdGJYeVE5czBsSTUzOXl5c21qekVpMHZkVGU5VVJjOTdLTVBLNW9mRWRCNGZzcXF4LTZhQk4xTWJBbjhFaXFEdFk2MWRfa0NXNHpZeXdaNV9wb0pMZ2U2aU9mRUZKSS1CcEVJT2thY3otUEVXeWRsRE9kTEVR?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T21:41:19+00:00", "published_display": "14 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Tuesday's After-Market Session", "summary": "This article lists 12 healthcare stocks that experienced significant movement during Tuesday's after-market trading session. It details both gainers like Exicure (XCUR) and Catheter Precision (VTAK), which saw increases of 38.4% and 21.23% respectively, and losers such as Basel M", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60458411/12-health-care-stocks-moving-tuesday-s-after-market-session", "source_name": "Benzinga", "published_at": "2026-07-14T20:40:55", "published_display": "14 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc. (XCUR) Q2 2022 Earnings: Significant Earnings Miss and Negative Stock Reaction - Earnings Sentiment Score", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNS2FnMTgxMkdmemJMVm9FTW11SEdWWjU1U053aGl2TF95cmo1ZnFBVWJXTjA4a0x6Qk5oMzVSbUpDZWVIVHpjajR5UzJZVThGU29VdDZoVlo5RXZGUVllUHI5TE5fN3VsNFppMVJ3M0p3Q3lYVUltWlRtamhKeXFDX1Bvd2YtbzVGQWpCazZ6c1kwQlktSmwzMzhVbjludmp3eTk4c3BsT29pc0FhNGdyR3pyS1I2aXl5YXRfeXlDcUw3eU14TFQ0?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-13T17:44:06+00:00", "published_display": "13 Jul 2026 17:44", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Exicure Inc. (XCUR) Affects Rotational Strategy Timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOeF85RUgtbUR6MUlDWE93cjVOWWlHVWpvWkk0TVoyN0owMENNOExyZm1RdWNNWW1xcC0wR01VQ3FERG11akNyeDlRNGNGZURYM0pPMFZ0N1lzWGNJQ0tWeVhpMU5lenVvSkNXZXFfSlcyaU1UbS1TQlFabk1Ic0JUdTNzN3o5eGpVWWlJNGlkM1NyYzgtWV9qTnYza0NnbWVIdmNpbmxvQThrWFRmZ05na21WX0c0SU51WXhpWmt0TlI3ZlZSdXplQmpNakdrdUlz?oc=5", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T16:18:02+00:00", "published_display": "13 Jul 2026 16:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Exicure Inc. (XCUR) Slips 7.89%: Key Support Levels Under Scrutiny - Dark Pool Prints", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQV0tiY0VNMHVMYUwwMV82dURoOGdjWjlzcndwelhkVTFHbDZGWUJ6NjFHOXVfOGd3TU00bFFGUklyOWFoWW5mWjNHQmVZQ2I3dG5IUTh5V0VzMnRZTUpZLV9aZmlIYTROR1hvdDAtaVV5VnJzQjU1SVUzU2E5NWFkcVFlNVp6R0QyQjFlcGlXM01KZnBaQXA1TUhYTDZ6SENRbDVIQ3JOQkk?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc. (XCUR) Slips 7.89%: Key Support Levels Under Scrutiny - Volatility Skew", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOOTBVcTJ3RXA1eXZUTEkyM2dLTHFvUVZwUUVHRV9FNGVIQTB6cnRid0dpZS1HcDBYME9paFlDNkYwd1VBaXhBZWtJVV9VRjk4ZDZsay1LamdneGh2b0JXZEJhcmRXTk5OMUZEOERGakFRZlNteEJlVDlRek05TjgwZFFBSy05TVBwRGRMeXd6cUdCMFpmY25sVDN5Zm5GMnFNRW94TnNR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure stock holds its line. Company context stays front and center.", "summary": "Exicure (XCUR) stock remains tied to its corporate profile and Nasdaq listing context, as investors focus on the company's background, filings, and operating setup due to the absence of a clear, immediate catalyst. The company's business history in biotech research and developmen", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exicure-stock-holds-its-line-company-context-stays-front-and-center/69715737", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:40:23", "published_display": "07 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Debt to assets ratio of Exicure, Inc. \u2013 DUS:2H0", "summary": "The article focuses on the debt to assets ratio of Exicure, Inc. (DUS:2H0), a biotechnology company listed on the Dusseldorf Stock Exchange. It provides context for accessing this financial metric within the TradingView platform, emphasizing its availability under the \"Financials", "url": "https://www.tradingview.com/symbols/DUS-2H0/financials-statistics-and-ratios/debt-to-asset/", "source_name": "TradingView", "published_at": "2026-07-07T12:11:20", "published_display": "07 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Non-controlling/minority interest of Exicure, Inc. \u2013 DUS:2H0", "summary": "This article provides financial information for Exicure, Inc., specifically focusing on its non-controlling/minority interest under the ticker DUS:2H0 on the Dusseldorf Stock Exchange. It indicates that the market was closed with no trades at the time of publication. The content ", "url": "https://www.tradingview.com/symbols/DUS-2H0/financials-income-statement/minority-interest-exp/", "source_name": "TradingView", "published_at": "2026-07-05T11:40:58", "published_display": "05 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Exicure, Inc. \u2013 NASDAQ:XCUR", "summary": "This article provides financial information for Exicure, Inc. (NASDAQ: XCUR), specifically focusing on its enterprise value to EBITDA forward metric. The content highlights the company's stock information, market status, and references financial data providers like ICE Data Servi", "url": "https://www.tradingview.com/symbols/NASDAQ-XCUR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T10:39:56", "published_display": "04 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure stock leans on its cash position. Nasdaq listing keeps it visible.", "summary": "Exicure Inc. (XCUR) is a Nasdaq-listed biotechnology company whose stock performance is currently driven by its cash position, Nasdaq listing visibility, and future corporate updates rather than immediate product news. The company focuses on early-stage nucleic-acid-based therapi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exicure-stock-leans-on-its-cash-position-nasdaq-listing-keeps-it-visible/69681965", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T17:41:17", "published_display": "03 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure announces board changes, adds two new directors By Investing.com", "summary": "Exicure (NASDAQ:XCUR) announced changes to its board of directors, including the resignation of Jung Kyu Ham and the appointment of Jin Young Go and Eui Seok Han as new Class III directors. These changes come as the biotechnology company's stock has declined significantly and it ", "url": "https://ng.investing.com/news/stock-market-news/exicure-announces-board-changes-adds-two-new-directors-93CH-2580196", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T09:09:59", "published_display": "01 Jul 2026 09:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Announces Board and Committee Changes", "summary": "Exicure, Inc. has announced several changes to its Board of Directors and Board committees. Jung Kyu Ham resigned as a director, and Jin Young Go was appointed as a Class III director. The Board also increased its size from five to six directors, appointing Eui Seok Han as a Clas", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/exicure-announces-board-and-committee-changes/2375817", "source_name": "The Manila Times", "published_at": "2026-06-30T20:39:59", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New directors join Exicure (NASDAQ: XCUR) board as compensation committee forms", "summary": "Exicure (NASDAQ: XCUR) is restructuring its board, with director Ham Jung Kyu resigning and two new Class III directors, Han Eui Seok and Go Jin Young, joining effective June 30, 2026, increasing the board size from five to six. Concurrently, the company established a new Compens", "url": "https://www.stocktitan.net/sec-filings/XCUR/8-k-exicure-inc-reports-material-event-3ca298395c92.html", "source_name": "Stock Titan", "published_at": "2026-06-30T18:56:22", "published_display": "30 Jun 2026 18:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure announces board changes, adds two new directors", "summary": "Exicure, Inc. (NASDAQ:XCUR) announced changes to its board of directors, including the resignation of Jung Kyu Ham and the appointment of Jin Young Go and Eui Seok Han as new Class III directors. These changes expand the board to six members, maintaining Nasdaq's independence req", "url": "https://www.investing.com/news/company-news/exicure-announces-board-changes-adds-two-new-directors-93CH-4767913", "source_name": "Investing.com", "published_at": "2026-06-30T12:40:29", "published_display": "30 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure expands board to 6, names 2 new directors", "summary": "Exicure (Nasdaq:XCUR) announced changes to its Board of Directors and Board committees, expanding its board from five to six members. Jin Young Go and Eui Seok Han were appointed Class III directors, with Han qualifying as an independent director under Nasdaq Listing Rules. The c", "url": "https://www.stocktitan.net/news/XCUR/exicure-announces-board-and-committee-kp4eqhrv0jvh.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:39:23", "published_display": "30 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure refreshes board with new independent directors", "summary": "Exicure (XCUR) announced a refresh of its board of directors, with Ham Jung Kyu resigning and Go Jin Young and Han Eui Seok appointed as new Class III directors. The company expanded its board from five to six members and formed a new Compensation Committee. These changes are aim", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3084825/exicure-refreshes-board-with-new-independent-directors/", "source_name": "The Globe and Mail", "published_at": "2026-06-29T12:11:20", "published_display": "29 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Exicure, Inc. \u2013 NASDAQ:XCUR", "summary": "This article provides the \"Price to book forward\" financial metric for Exicure, Inc. (NASDAQ: XCUR). The content is primarily a data point within a larger financial platform, indicating the value and change of this specific financial ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-XCUR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:40:01", "published_display": "28 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Exicure, Inc. \u2013 NASDAQ:XCUR", "summary": "This article displays the \"Price to earnings forward\" metric for Exicure, Inc. (NASDAQ: XCUR). The page is primarily a data placeholder from TradingView, indicating that specific financial data for this metric exists and can be viewed for various periods, though no actual values ", "url": "https://www.tradingview.com/symbols/NASDAQ-XCUR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:08:59", "published_display": "27 Jun 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure, Inc. Actuals & Estimates (NASDAQ:XCUR)", "summary": "This article provides an overview of Exicure, Inc. (NASDAQ:XCUR) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, upcoming earnings dates, and key financial metrics like net income. The company currently h", "url": "https://www.tradingview.com/symbols/NASDAQ-XCUR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:36", "published_display": "26 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc (XCUR) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Exicure Inc (XCUR), noting its current valuation score is 8.72, ranking 99th out of 388 in its industry. It highlights the company's P/E ratio of -3.42, which is significantly below its recent high and above its recent low. However, i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xcur/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T17:10:28", "published_display": "23 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value of Exicure, Inc. \u2013 DUS:2H0", "summary": "This article focuses on the enterprise value of Exicure, Inc. (DUS:2H0) as presented on TradingView. It indicates that the market for this financial instrument is currently closed with no trades. The page provides an overview of financials, news, and community related to Exicure,", "url": "https://www.tradingview.com/symbols/DUS-2H0/financials-statistics-and-ratios/enterprise-value/", "source_name": "TradingView", "published_at": "2026-06-18T16:10:44", "published_display": "18 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash from operating activities of Exicure, Inc. \u2013 DUS:2H0", "summary": "This article focuses on the \"Cash from operating activities\" for Exicure, Inc. (DUS:2H0), a company listed on the Dusseldorf Stock Exchange. The content appears to be a financial data point from a trading platform, indicating specific values and percentage changes over a period, ", "url": "https://www.tradingview.com/symbols/DUS-2H0/financials-cash-flow/cash-f-operating-activities/", "source_name": "TradingView", "published_at": "2026-06-18T15:41:34", "published_display": "18 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc (XCUR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Exicure Inc (XCUR), noting its current financial score of 4.76 and ranking it 383 out of 389 in the Biotechnology & Medical Research industry. While the company's financial status is robust, its operating efficiency is low. The report", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xcur/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T15:09:37", "published_display": "18 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total equity of Exicure, Inc. \u2013 DUS:2H0", "summary": "This article provides financial information for Exicure, Inc. (DUS:2H0), specifically focusing on its total equity. The content is sourced from TradingView and includes data from ICE Data Services and FactSet, along with SEC filings from Quartr.", "url": "https://www.tradingview.com/symbols/DUS-2H0/financials-balance-sheet/total-equity/", "source_name": "TradingView", "published_at": "2026-06-18T11:10:11", "published_display": "18 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure, Inc. Balance Sheet \u2013 DUS:2H0", "summary": "This article provides details on Exicure, Inc.'s balance sheet (DUS:2H0), highlighting its financial position as of Q1 2026. The company's total assets were 11.04 million EUR, a 12.68% decrease from Q4 2025, while total liabilities decreased by 0.83% to 9.22 million EUR in the sa", "url": "https://www.tradingview.com/symbols/DUS-2H0/financials-balance-sheet/", "source_name": "TradingView", "published_at": "2026-06-18T10:10:12", "published_display": "18 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc (XCUR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Exicure Inc's (XCUR) dividend and stock split history. It notes that the company has distributed no dividends over the past five years but details several merger-related stock splits, including one recently on August 26, 2024, at a 5-to-1 rati", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xcur/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:12", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders\u2019 Equity Requirement", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/exicure-announces-receipt-nasdaq-notice-200100473.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T20:01:00+00:00", "published_display": "10 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure faces Nasdaq listing deadline as equity sits at $2.1M vs $2.5M", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxObm00VEJCUzBKbXhzbGdKQ2hPY1NBWTVlT1B3LUpnTnN0MmtrcHVRSjJLdW5lbmM5LXdqTzRKUkZjSGVwVVd3OUVoUlhYd0R0WUdEeFRtOXo5V0tubVBaalpMV084Um1pWC1zbVhRaTFNbXdtZHF1TGt6MFV6WnBxdnF2cmhHcmxHRjBTSzhjbEF1N19JbFBMbEt5TTNvLW1jcmlwNkR0M3FLVkFOS3Q5dU8xVGR4UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/exicure-announces-receipt-nasdaq-delinquency-200000770.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T20:00:00+00:00", "published_display": "01 Jun 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure faces Nasdaq noncompliance over late 10-Q, then files report", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNWkQ5eDRmamJvN1BYenVqd1B3NHRnWmFNeF9TV3Y3U05qM0Z6cEVLWWNvb2RIaVVBRHZHdldvazZURnpLd3RsZVpzZGlsQ0ttUURBSGJlSjZjZG1vSzVPMVFMRzFNaWJJdUY5eXJDckZMc3poU0J2ZC0yS0VUX2lMUkMybEQwZ192Z1d1ME5vUGhUVFZ4d3pldUxGTWJydzdrSFFXNXEyTEg4R0hKZmZtcGxOSzFIOEVad2JIRlE2ZGQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc. (XCUR) Q2 2022 Earnings: Wider-than-Expected Loss, No Revenue, Shares Edge Higher - Margin Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOeEpFa1J3ZDZqbmtyNEkxSnpSNzVVZEs0SGJBQmszbV96TDRUTGtxOWxhZEpVM2Q3emlWdVZOdmtvZjBkbFkyd2RVc0JRcmFHWFJ2X090LVpjS2FYaktxUXJwMzBvNVI5RXdLUmd0aGRrLUJoUldxWnU2RF8zMFMwNVJuVDROYTZHcWdqZUxNX3ZnYktIOGs0M3NZYkl1Z0l6V1JCWjlVWFBfcmlVZDBlUEZuQ0N6RVpDYlZCUVVkamw5eG1UTnI0?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Exicure, Inc. Reports Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPWlJEQ18tdnVMUnZkZXZMRkNBSmFUZDVIZjMySXllYkRQVURLS1YzbU9salFORU9mZEMtYjBmbmJEeWYySHlMRXVuY0cwYkRTZnZuZlFHRzJOcnJjem9UM283RkstaElZczAzc21ySHpWZE8tTnFhMzNnT3U5emZfYnZ3TThGUUNBV0F1WFczVW5UT1l5WTlWaUJsXzMtNGJzcl9sNVZMTU9veFZxcG91bXpjNll5c1FPOWRZNWpCT3hCUm5XaGVULWlveUN4eF9aZ0RKdA?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics\u2019 U.S. Unit: Retail Chatter Spikes", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNaUJDWVdrTzU1dURqb2tjUjU5REV5Z0hxTDVVUzJxMDJVeWZDN1BENHBINUpUQVkzYmtMb25TRm8tY2d4NmZwZEt6SUwwbTF0cEljUm90NzllYnhRY0kxQ1liR0p6NVRsUzktX2RZRm1rQXZOY1NtOUZ1anBYVU0teWhvS291b1hwQ1VHMGVmajBEQldMaGY0?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell Alert: Hitron Exicure Sells 734,747 Shares of Exicu", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNQWZwOUUxRTRmeVU5VWFBWDFUZWJaYzNrNWJIdUdqZlJ1MmNheWwtUjdGeU9YUWhuVDNPYjgzQ2djWEhOUm9WX01oRUFnSm1PVmlpWVBwcGk4djAtVVpxQjAtTndnQ2o2b1kwcmU4YVBiZTVzTTd4VmtfVHBmMmd0cUNyVzVxZlBEWmR2S1RxVXIwX0xCTEtJVmZqTFgtR1k5RlJHdkRpaEJqWFJ1Z1lmX3BSLURIQzVpTVVhdzFtVGtqRDI2QXE1cGVJbUlvaXVZUElaT0pzMA?oc=5", "source_name": "GuruFocus", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc.: Is It a Bet Worth Taking?", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE9Obm5QamZsRWRobTRpUlNTUUdjdFd3cFBvOTVFR05wUUgyc3M2ODcxUGJJRkpVWkdVQThBVjdkTWpKWlNRUWhQWlMxdVpGM3VrRVNDcDRzdmZxSVFCM0lNVjZwYTdIbExtT0NUZWlnN3pBd09tSWc?oc=5", "source_name": "timothysykes.com", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPa25EM1p4RlNrOU5sVTR2RmdaNzZZSmlFb0RSV3Z6Qy11eEZpN3hUZlBJX1RrR3Z3ZUVzX0hKdV9lOXpQcGFBWVg4NUIyeTdCZ0lnSjhBVzJWUG5lSVN0OHVjeDREd3o2SWVLV2FYdWNfQkVwVS05RkJkbHNlN2ViNE40SkFxOFdVdlhhWG85NHVnVDFYZUhWRTVuNnd5bUdvVDhJd0hCRlBNMU0?oc=5", "source_name": "BioSpace", "published_at": "2025-01-23T08:00:00+00:00", "published_display": "23 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Acquires GPCR Therapeutics USA, Signs Major Licensing Deal for Drug Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSkNOenpfRWFoNlJZRzhsTDZzZzJXcHlUZEk0NHBXWGRKYVB0cFBvVFNOYlZIeEI4X05hb3FsNmItQTd6RElEUnhDbGN4ZHN2a3VfaVZnNmF0TEVjVEZkZk1Wc1VmMkRKX01IQWIzSjVzMnItQ0JLYlR2RndUMVczMFZxbk5NQUpYNExNeVhfeTFYZEZ2VE9SQmY0d3FaTHF0M0VtUll0TmFGTzdpWGI5ampaWHBuYzZWQXc?oc=5", "source_name": "Stock Titan", "published_at": "2025-01-22T08:00:00+00:00", "published_display": "22 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech company Exicure's new path isn't in biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQUTVBNjdrR2JrclRpYk4xQzU3MEZQbXFxLVB3bDBkdlp1WmVLOFU3TTBmYk55VDhNSVd0V2RFYzllUERqS2JGazVWWXBCQ0tPUXhSNmZqcUR3S05fbXJUN2xKbFJUZUROMHE0N2R1LVJfS3BnNnJDVUZqT0gtQmJfT2NyazVYRF9HY1F6aWhyWUFOdVRRRHF3?oc=5", "source_name": "Crain's Chicago Business", "published_at": "2023-05-08T07:00:00+00:00", "published_display": "08 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "XCUR stock trades on limited evidence as Exicure waits for filings", "summary": "Exicure Inc. (XCUR) stock is currently trading with limited market drivers, with the company's investor relations site being the primary source of information. The article emphasizes that without recent filings, fresh market data, or updated operational figures, any analysis must", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/xcur-stock-trades-on-limited-evidence-as-exicure-waits-for-filings/69855923", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-23T19:09:28", "published_display": "23 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XCUR|Exicure Inc|Price:1.700|Chg%:-0.010", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9VTDlZOGZJNzNBMFJpVUM5Q01aVzd6MmlxdE1Yekd2cks0dzUyNm9NS3BTNFdER3hpbVVCZGdnLU1MOVh4Sm5DSzZsVUZ3YXZ6U3FNUFY1TjZXQQ?oc=5", "source_name": "TradingKey", "published_at": "2026-07-23T07:00:00+00:00", "published_display": "23 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A EXICURE For: 17 July By Investing.com", "summary": "This article announces the filing of Form 13D/A for EXICURE, dated July 17. The brief report from Investing.com provides a headline update regarding this financial filing.", "url": "https://ng.investing.com/news/stock-market-news/form-13da-exicure-for-17-july-93CH-2605501", "source_name": "Investing.com Nigeria", "published_at": "2026-07-18T14:41:45", "published_display": "18 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Exicure Inc For: 17 July By Investing.com", "summary": "This article provides notification of a Form 4 filing for Exicure Inc. from July 17. Form 4 filings are used to report changes in beneficial ownership of a company's securities by insiders. The article also lists the current stock performance of XCUR for the day mentioned.", "url": "https://ng.investing.com/news/stock-market-news/form-4-exicure-inc-for-17-july-93CH-2605739", "source_name": "Investing.com Nigeria", "published_at": "2026-07-17T21:44:00", "published_display": "17 Jul 2026 21:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure, Inc. (XCUR) holder Exicure HiTron regains 623,275 returned shares", "summary": "Exicure HiTron Inc., a major shareholder of EXICURE, INC. (XCUR), has reported the acquisition of 623,275 common shares through a series of \"code J\" transactions between June 23 and July 8, 2026, each priced at $4.50. These shares were returned to Exicure HiTron due to share tran", "url": "https://www.stocktitan.net/sec-filings/XCUR/form-4-exicure-inc-insider-trading-activity-4d6da06defb5.html", "source_name": "Stock Titan", "published_at": "2026-07-17T20:39:30", "published_display": "17 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure HiTron boosts Exicure (XCUR) holding to 2.22M shares, 34.87%", "summary": "Exicure HiTron Inc. has increased its beneficial ownership in Exicure, Inc. (XCUR) to 34.87%, holding 2,222,224 shares after amending previous share transfer transactions. This change resulted from five purchasers returning an aggregate of 623,277 Exicure shares to Exicure HiTron", "url": "https://www.stocktitan.net/sec-filings/XCUR/schedule-13d-a-exicure-inc-amended-major-shareholder-report-94ca3cb0d3a4.html", "source_name": "Stock Titan", "published_at": "2026-07-17T16:39:30", "published_display": "17 Jul 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | Exicure Shoots up 31.39% Post-Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOU1F2ekItTVVJS3lyWVc4RmxZSndvVy1MMlAyWWJNal9iQ0RsdGJYeVE5czBsSTUzOXl5c21qekVpMHZkVGU5VVJjOTdLTVBLNW9mRWRCNGZzcXF4LTZhQk4xTWJBbjhFaXFEdFk2MWRfa0NXNHpZeXdaNV9wb0pMZ2U2aU9mRUZKSS1CcEVJT2thY3otUEVXeWRsRE9kTEVR?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T21:41:19+00:00", "published_display": "14 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Tuesday's After-Market Session", "summary": "This article lists 12 healthcare stocks that experienced significant movement during Tuesday's after-market trading session. It details both gainers like Exicure (XCUR) and Catheter Precision (VTAK), which saw increases of 38.4% and 21.23% respectively, and losers such as Basel M", "url": "https://www.benzinga.com/trading-ideas/movers/26/07/60458411/12-health-care-stocks-moving-tuesday-s-after-market-session", "source_name": "Benzinga", "published_at": "2026-07-14T20:40:55", "published_display": "14 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc. (XCUR) Q2 2022 Earnings: Significant Earnings Miss and Negative Stock Reaction - Earnings Sentiment Score", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNS2FnMTgxMkdmemJMVm9FTW11SEdWWjU1U053aGl2TF95cmo1ZnFBVWJXTjA4a0x6Qk5oMzVSbUpDZWVIVHpjajR5UzJZVThGU29VdDZoVlo5RXZGUVllUHI5TE5fN3VsNFppMVJ3M0p3Q3lYVUltWlRtamhKeXFDX1Bvd2YtbzVGQWpCazZ6c1kwQlktSmwzMzhVbjludmp3eTk4c3BsT29pc0FhNGdyR3pyS1I2aXl5YXRfeXlDcUw3eU14TFQ0?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-13T17:44:06+00:00", "published_display": "13 Jul 2026 17:44", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Exicure Inc. (XCUR) Affects Rotational Strategy Timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOeF85RUgtbUR6MUlDWE93cjVOWWlHVWpvWkk0TVoyN0owMENNOExyZm1RdWNNWW1xcC0wR01VQ3FERG11akNyeDlRNGNGZURYM0pPMFZ0N1lzWGNJQ0tWeVhpMU5lenVvSkNXZXFfSlcyaU1UbS1TQlFabk1Ic0JUdTNzN3o5eGpVWWlJNGlkM1NyYzgtWV9qTnYza0NnbWVIdmNpbmxvQThrWFRmZ05na21WX0c0SU51WXhpWmt0TlI3ZlZSdXplQmpNakdrdUlz?oc=5", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T16:18:02+00:00", "published_display": "13 Jul 2026 16:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc. (XCUR) Slips 7.89%: Key Support Levels Under Scrutiny - Dark Pool Prints", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQV0tiY0VNMHVMYUwwMV82dURoOGdjWjlzcndwelhkVTFHbDZGWUJ6NjFHOXVfOGd3TU00bFFGUklyOWFoWW5mWjNHQmVZQ2I3dG5IUTh5V0VzMnRZTUpZLV9aZmlIYTROR1hvdDAtaVV5VnJzQjU1SVUzU2E5NWFkcVFlNVp6R0QyQjFlcGlXM01KZnBaQXA1TUhYTDZ6SENRbDVIQ3JOQkk?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc. (XCUR) Slips 7.89%: Key Support Levels Under Scrutiny - Volatility Skew", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOOTBVcTJ3RXA1eXZUTEkyM2dLTHFvUVZwUUVHRV9FNGVIQTB6cnRid0dpZS1HcDBYME9paFlDNkYwd1VBaXhBZWtJVV9VRjk4ZDZsay1LamdneGh2b0JXZEJhcmRXTk5OMUZEOERGakFRZlNteEJlVDlRek05TjgwZFFBSy05TVBwRGRMeXd6cUdCMFpmY25sVDN5Zm5GMnFNRW94TnNR?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure stock holds its line. Company context stays front and center.", "summary": "Exicure (XCUR) stock remains tied to its corporate profile and Nasdaq listing context, as investors focus on the company's background, filings, and operating setup due to the absence of a clear, immediate catalyst. The company's business history in biotech research and developmen", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exicure-stock-holds-its-line-company-context-stays-front-and-center/69715737", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:40:23", "published_display": "07 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Debt to assets ratio of Exicure, Inc. \u2013 DUS:2H0", "summary": "The article focuses on the debt to assets ratio of Exicure, Inc. (DUS:2H0), a biotechnology company listed on the Dusseldorf Stock Exchange. It provides context for accessing this financial metric within the TradingView platform, emphasizing its availability under the \"Financials", "url": "https://www.tradingview.com/symbols/DUS-2H0/financials-statistics-and-ratios/debt-to-asset/", "source_name": "TradingView", "published_at": "2026-07-07T12:11:20", "published_display": "07 Jul 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Non-controlling/minority interest of Exicure, Inc. \u2013 DUS:2H0", "summary": "This article provides financial information for Exicure, Inc., specifically focusing on its non-controlling/minority interest under the ticker DUS:2H0 on the Dusseldorf Stock Exchange. It indicates that the market was closed with no trades at the time of publication. The content ", "url": "https://www.tradingview.com/symbols/DUS-2H0/financials-income-statement/minority-interest-exp/", "source_name": "TradingView", "published_at": "2026-07-05T11:40:58", "published_display": "05 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Exicure, Inc. \u2013 NASDAQ:XCUR", "summary": "This article provides financial information for Exicure, Inc. (NASDAQ: XCUR), specifically focusing on its enterprise value to EBITDA forward metric. The content highlights the company's stock information, market status, and references financial data providers like ICE Data Servi", "url": "https://www.tradingview.com/symbols/NASDAQ-XCUR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T10:39:56", "published_display": "04 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure stock leans on its cash position. Nasdaq listing keeps it visible.", "summary": "Exicure Inc. (XCUR) is a Nasdaq-listed biotechnology company whose stock performance is currently driven by its cash position, Nasdaq listing visibility, and future corporate updates rather than immediate product news. The company focuses on early-stage nucleic-acid-based therapi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exicure-stock-leans-on-its-cash-position-nasdaq-listing-keeps-it-visible/69681965", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T17:41:17", "published_display": "03 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure announces board changes, adds two new directors By Investing.com", "summary": "Exicure (NASDAQ:XCUR) announced changes to its board of directors, including the resignation of Jung Kyu Ham and the appointment of Jin Young Go and Eui Seok Han as new Class III directors. These changes come as the biotechnology company's stock has declined significantly and it ", "url": "https://ng.investing.com/news/stock-market-news/exicure-announces-board-changes-adds-two-new-directors-93CH-2580196", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T09:09:59", "published_display": "01 Jul 2026 09:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Announces Board and Committee Changes", "summary": "Exicure, Inc. has announced several changes to its Board of Directors and Board committees. Jung Kyu Ham resigned as a director, and Jin Young Go was appointed as a Class III director. The Board also increased its size from five to six directors, appointing Eui Seok Han as a Clas", "url": "https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/exicure-announces-board-and-committee-changes/2375817", "source_name": "The Manila Times", "published_at": "2026-06-30T20:39:59", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New directors join Exicure (NASDAQ: XCUR) board as compensation committee forms", "summary": "Exicure (NASDAQ: XCUR) is restructuring its board, with director Ham Jung Kyu resigning and two new Class III directors, Han Eui Seok and Go Jin Young, joining effective June 30, 2026, increasing the board size from five to six. Concurrently, the company established a new Compens", "url": "https://www.stocktitan.net/sec-filings/XCUR/8-k-exicure-inc-reports-material-event-3ca298395c92.html", "source_name": "Stock Titan", "published_at": "2026-06-30T18:56:22", "published_display": "30 Jun 2026 18:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure announces board changes, adds two new directors", "summary": "Exicure, Inc. (NASDAQ:XCUR) announced changes to its board of directors, including the resignation of Jung Kyu Ham and the appointment of Jin Young Go and Eui Seok Han as new Class III directors. These changes expand the board to six members, maintaining Nasdaq's independence req", "url": "https://www.investing.com/news/company-news/exicure-announces-board-changes-adds-two-new-directors-93CH-4767913", "source_name": "Investing.com", "published_at": "2026-06-30T12:40:29", "published_display": "30 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure expands board to 6, names 2 new directors", "summary": "Exicure (Nasdaq:XCUR) announced changes to its Board of Directors and Board committees, expanding its board from five to six members. Jin Young Go and Eui Seok Han were appointed Class III directors, with Han qualifying as an independent director under Nasdaq Listing Rules. The c", "url": "https://www.stocktitan.net/news/XCUR/exicure-announces-board-and-committee-kp4eqhrv0jvh.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:39:23", "published_display": "30 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure refreshes board with new independent directors", "summary": "Exicure (XCUR) announced a refresh of its board of directors, with Ham Jung Kyu resigning and Go Jin Young and Han Eui Seok appointed as new Class III directors. The company expanded its board from five to six members and formed a new Compensation Committee. These changes are aim", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3084825/exicure-refreshes-board-with-new-independent-directors/", "source_name": "The Globe and Mail", "published_at": "2026-06-29T12:11:20", "published_display": "29 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Exicure, Inc. \u2013 NASDAQ:XCUR", "summary": "This article provides the \"Price to book forward\" financial metric for Exicure, Inc. (NASDAQ: XCUR). The content is primarily a data point within a larger financial platform, indicating the value and change of this specific financial ratio for the company.", "url": "https://www.tradingview.com/symbols/NASDAQ-XCUR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:40:01", "published_display": "28 Jun 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Exicure, Inc. \u2013 NASDAQ:XCUR", "summary": "This article displays the \"Price to earnings forward\" metric for Exicure, Inc. (NASDAQ: XCUR). The page is primarily a data placeholder from TradingView, indicating that specific financial data for this metric exists and can be viewed for various periods, though no actual values ", "url": "https://www.tradingview.com/symbols/NASDAQ-XCUR/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T14:08:59", "published_display": "27 Jun 2026 14:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure, Inc. Actuals & Estimates (NASDAQ:XCUR)", "summary": "This article provides an overview of Exicure, Inc. (NASDAQ:XCUR) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, upcoming earnings dates, and key financial metrics like net income. The company currently h", "url": "https://www.tradingview.com/symbols/NASDAQ-XCUR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:36", "published_display": "26 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc (XCUR) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Exicure Inc (XCUR), noting its current valuation score is 8.72, ranking 99th out of 388 in its industry. It highlights the company's P/E ratio of -3.42, which is significantly below its recent high and above its recent low. However, i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xcur/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T17:10:28", "published_display": "23 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value of Exicure, Inc. \u2013 DUS:2H0", "summary": "This article focuses on the enterprise value of Exicure, Inc. (DUS:2H0) as presented on TradingView. It indicates that the market for this financial instrument is currently closed with no trades. The page provides an overview of financials, news, and community related to Exicure,", "url": "https://www.tradingview.com/symbols/DUS-2H0/financials-statistics-and-ratios/enterprise-value/", "source_name": "TradingView", "published_at": "2026-06-18T16:10:44", "published_display": "18 Jun 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash from operating activities of Exicure, Inc. \u2013 DUS:2H0", "summary": "This article focuses on the \"Cash from operating activities\" for Exicure, Inc. (DUS:2H0), a company listed on the Dusseldorf Stock Exchange. The content appears to be a financial data point from a trading platform, indicating specific values and percentage changes over a period, ", "url": "https://www.tradingview.com/symbols/DUS-2H0/financials-cash-flow/cash-f-operating-activities/", "source_name": "TradingView", "published_at": "2026-06-18T15:41:34", "published_display": "18 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc (XCUR) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Exicure Inc (XCUR), noting its current financial score of 4.76 and ranking it 383 out of 389 in the Biotechnology & Medical Research industry. While the company's financial status is robust, its operating efficiency is low. The report", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xcur/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T15:09:37", "published_display": "18 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Total equity of Exicure, Inc. \u2013 DUS:2H0", "summary": "This article provides financial information for Exicure, Inc. (DUS:2H0), specifically focusing on its total equity. The content is sourced from TradingView and includes data from ICE Data Services and FactSet, along with SEC filings from Quartr.", "url": "https://www.tradingview.com/symbols/DUS-2H0/financials-balance-sheet/total-equity/", "source_name": "TradingView", "published_at": "2026-06-18T11:10:11", "published_display": "18 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure, Inc. Balance Sheet \u2013 DUS:2H0", "summary": "This article provides details on Exicure, Inc.'s balance sheet (DUS:2H0), highlighting its financial position as of Q1 2026. The company's total assets were 11.04 million EUR, a 12.68% decrease from Q4 2025, while total liabilities decreased by 0.83% to 9.22 million EUR in the sa", "url": "https://www.tradingview.com/symbols/DUS-2H0/financials-balance-sheet/", "source_name": "TradingView", "published_at": "2026-06-18T10:10:12", "published_display": "18 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc (XCUR) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Exicure Inc's (XCUR) dividend and stock split history. It notes that the company has distributed no dividends over the past five years but details several merger-related stock splits, including one recently on August 26, 2024, at a 5-to-1 rati", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xcur/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T05:10:12", "published_display": "18 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders\u2019 Equity Requirement", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/exicure-announces-receipt-nasdaq-notice-200100473.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T20:01:00+00:00", "published_display": "10 Jun 2026 20:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure faces Nasdaq listing deadline as equity sits at $2.1M vs $2.5M", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxObm00VEJCUzBKbXhzbGdKQ2hPY1NBWTVlT1B3LUpnTnN0MmtrcHVRSjJLdW5lbmM5LXdqTzRKUkZjSGVwVVd3OUVoUlhYd0R0WUdEeFRtOXo5V0tubVBaalpMV084Um1pWC1zbVhRaTFNbXdtZHF1TGt6MFV6WnBxdnF2cmhHcmxHRjBTSzhjbEF1N19JbFBMbEt5TTNvLW1jcmlwNkR0M3FLVkFOS3Q5dU8xVGR4UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/exicure-announces-receipt-nasdaq-delinquency-200000770.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T20:00:00+00:00", "published_display": "01 Jun 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure faces Nasdaq noncompliance over late 10-Q, then files report", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNWkQ5eDRmamJvN1BYenVqd1B3NHRnWmFNeF9TV3Y3U05qM0Z6cEVLWWNvb2RIaVVBRHZHdldvazZURnpLd3RsZVpzZGlsQ0ttUURBSGJlSjZjZG1vSzVPMVFMRzFNaWJJdUY5eXJDckZMc3poU0J2ZC0yS0VUX2lMUkMybEQwZ192Z1d1ME5vUGhUVFZ4d3pldUxGTWJydzdrSFFXNXEyTEg4R0hKZmZtcGxOSzFIOEVad2JIRlE2ZGQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc. (XCUR) Q2 2022 Earnings: Wider-than-Expected Loss, No Revenue, Shares Edge Higher - Margin Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOeEpFa1J3ZDZqbmtyNEkxSnpSNzVVZEs0SGJBQmszbV96TDRUTGtxOWxhZEpVM2Q3emlWdVZOdmtvZjBkbFkyd2RVc0JRcmFHWFJ2X090LVpjS2FYaktxUXJwMzBvNVI5RXdLUmd0aGRrLUJoUldxWnU2RF8zMFMwNVJuVDROYTZHcWdqZUxNX3ZnYktIOGs0M3NZYkl1Z0l6V1JCWjlVWFBfcmlVZDBlUEZuQ0N6RVpDYlZCUVVkamw5eG1UTnI0?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure, Inc. Reports Full Year 2025 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxPWlJEQ18tdnVMUnZkZXZMRkNBSmFUZDVIZjMySXllYkRQVURLS1YzbU9salFORU9mZEMtYjBmbmJEeWYySHlMRXVuY0cwYkRTZnZuZlFHRzJOcnJjem9UM283RkstaElZczAzc21ySHpWZE8tTnFhMzNnT3U5emZfYnZ3TThGUUNBV0F1WFczVW5UT1l5WTlWaUJsXzMtNGJzcl9sNVZMTU9veFZxcG91bXpjNll5c1FPOWRZNWpCT3hCUm5XaGVULWlveUN4eF9aZ0RKdA?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics\u2019 U.S. Unit: Retail Chatter Spikes", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNaUJDWVdrTzU1dURqb2tjUjU5REV5Z0hxTDVVUzJxMDJVeWZDN1BENHBINUpUQVkzYmtMb25TRm8tY2d4NmZwZEt6SUwwbTF0cEljUm90NzllYnhRY0kxQ1liR0p6NVRsUzktX2RZRm1rQXZOY1NtOUZ1anBYVU0teWhvS291b1hwQ1VHMGVmajBEQldMaGY0?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell Alert: Hitron Exicure Sells 734,747 Shares of Exicu", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNQWZwOUUxRTRmeVU5VWFBWDFUZWJaYzNrNWJIdUdqZlJ1MmNheWwtUjdGeU9YUWhuVDNPYjgzQ2djWEhOUm9WX01oRUFnSm1PVmlpWVBwcGk4djAtVVpxQjAtTndnQ2o2b1kwcmU4YVBiZTVzTTd4VmtfVHBmMmd0cUNyVzVxZlBEWmR2S1RxVXIwX0xCTEtJVmZqTFgtR1k5RlJHdkRpaEJqWFJ1Z1lmX3BSLURIQzVpTVVhdzFtVGtqRDI2QXE1cGVJbUlvaXVZUElaT0pzMA?oc=5", "source_name": "GuruFocus", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Inc.: Is It a Bet Worth Taking?", "summary": "", "url": "https://news.google.com/rss/articles/CBMidkFVX3lxTE9Obm5QamZsRWRobTRpUlNTUUdjdFd3cFBvOTVFR05wUUgyc3M2ODcxUGJJRkpVWkdVQThBVjdkTWpKWlNRUWhQWlMxdVpGM3VrRVNDcDRzdmZxSVFCM0lNVjZwYTdIbExtT0NUZWlnN3pBd09tSWc?oc=5", "source_name": "timothysykes.com", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPa25EM1p4RlNrOU5sVTR2RmdaNzZZSmlFb0RSV3Z6Qy11eEZpN3hUZlBJX1RrR3Z3ZUVzX0hKdV9lOXpQcGFBWVg4NUIyeTdCZ0lnSjhBVzJWUG5lSVN0OHVjeDREd3o2SWVLV2FYdWNfQkVwVS05RkJkbHNlN2ViNE40SkFxOFdVdlhhWG85NHVnVDFYZUhWRTVuNnd5bUdvVDhJd0hCRlBNMU0?oc=5", "source_name": "BioSpace", "published_at": "2025-01-23T08:00:00+00:00", "published_display": "23 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exicure Acquires GPCR Therapeutics USA, Signs Major Licensing Deal for Drug Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSkNOenpfRWFoNlJZRzhsTDZzZzJXcHlUZEk0NHBXWGRKYVB0cFBvVFNOYlZIeEI4X05hb3FsNmItQTd6RElEUnhDbGN4ZHN2a3VfaVZnNmF0TEVjVEZkZk1Wc1VmMkRKX01IQWIzSjVzMnItQ0JLYlR2RndUMVczMFZxbk5NQUpYNExNeVhfeTFYZEZ2VE9SQmY0d3FaTHF0M0VtUll0TmFGTzdpWGI5ampaWHBuYzZWQXc?oc=5", "source_name": "Stock Titan", "published_at": "2025-01-22T08:00:00+00:00", "published_display": "22 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech company Exicure's new path isn't in biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQUTVBNjdrR2JrclRpYk4xQzU3MEZQbXFxLVB3bDBkdlp1WmVLOFU3TTBmYk55VDhNSVd0V2RFYzllUERqS2JGazVWWXBCQ0tPUXhSNmZqcUR3S05fbXJUN2xKbFJUZUROMHE0N2R1LVJfS3BnNnJDVUZqT0gtQmJfT2NyazVYRF9HY1F6aWhyWUFOdVRRRHF3?oc=5", "source_name": "Crain's Chicago Business", "published_at": "2023-05-08T07:00:00+00:00", "published_display": "08 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T07:00:00+00:00", "published_display": "16 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 87, "total_relevant": 54, "sentiment_summary": {"positive": 1, "negative": 6, "neutral": 47, "score": 48, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 18.15, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}], "positive_events": 1, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 1.68, "latest_week": "2026-07-17", "one_week_move": -4.0, "four_week_move": -27.3, "twelve_week_move": -51.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.268406, "market_dynamics_buy_signal": false, "relative_strength": -65.986721, "fair_value_gap": -69.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.9624, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.0% over one week, -27.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 11}, {"label": "Stock Titan", "count": 7}, {"label": "Market source", "count": 6}, {"label": "TradingKey", "count": 4}, {"label": "dars.gov.et", "count": 4}, {"label": "Investing.com Nigeria", "count": 3}, {"label": "Ad-hoc-news.de", "count": 2}, {"label": "The Globe and Mail", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 14}, {"label": "Deals and strategy", "count": 4}, {"label": "Balance sheet", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "48/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.0% over one week, -27.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "XCUR stock trades on limited evidence as Exicure waits for filings"}], "updated_at": "2026-07-24T15:40:28.930288+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}